Silvia Codenotti
University of Brescia
32 Papers
20 Citations
Silvia Codenotti is an academic researcher from University of Brescia. The author has contributed to research in topics: Rhabdomyosarcoma & Biology. The author has an hindex of 8, co-authored 19 publications. Previous affiliations of Silvia Codenotti include Brescia University.
Chat about Author
Papers
Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines
Silvia Codenotti,Maura Poli,Michela Asperti,Daniela Zizioli,Francesco Marampon,Alessandro Fanzani +5 more
TL;DR: The combination of erastin or RSL3 with chemotherapeutic doxorubicin and actinomycin D agents to be effective in increasing cell death in all RMS lines.
68
Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma.
Fiorella Faggi,Stefania Mitola,Guglielmo Sorci,Francesca Riuzzi,Rosario Donato,Silvia Codenotti,Pietro Luigi Poliani,Manuela Cominelli,Raffaella Vescovi,Stefania Rossi,Stefano Calza,Marina Colombi,Fabio Penna,Paola Costelli,Ilaria Perini,Maurilio Sampaolesi,Eugenio Monti,Alessandro Fanzani +17 more
TL;DR: All data point to pCav-1 as an important and therapeutically valuable target for overcoming the progression and multidrug resistance of RMS.
33
NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance
Francesco Marampon,Silvia Codenotti,Francesca Megiorni,Andrea Del Fattore,Simona Camero,Giovanni Luca Gravina,Claudio Festuccia,Daniela Musio,Francesca De Felice,Valerio Nardone,Anna Natalizia Santoro,Carlo Dominici,Alessandro Fanzani,Luigi Pirtoli,Antonella Fioravanti,Vincenzo Tombolini,Sara Cheleschi,Paolo Tini +17 more
TL;DR: The strategic role of oxidant/antioxidant balance in restraining the therapeutic efficiency of RT in RMS treatment is suggested and NRF2 is identified as a new potential molecular target whose inhibition might represent a novel radiosensitizing therapeutic strategy for RMS clinical management.
29
Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization.
Francesco Petragnano,Ilaria Pietrantoni,Simona Camero,Silvia Codenotti,Luisa Milazzo,Francesca Vulcano,Giampiero Macioce,Ilenia Giordani,Paolo Tini,Sara Cheleschi,Giovanni Luca Gravina,Claudio Festuccia,Alessandra Rossetti,Simona Delle Monache,Alessandra Ordinelli,Carmela Ciccarelli,Annunziata Mauro,Barboni Barbara,Cristina Antinozzi,Amalia Schiavetti,Roberto Maggio,Luigi Di Luigi,Antonella Polimeni,Cinzia Marchese,Vincenzo Tombolini,Alessandro Fanzani,Nicola Bernabò,Francesca Megiorni,Francesco Marampon +28 more
TL;DR: It is suggested that RMS could sustain intrinsic and acquire radioresistance by different mechanisms and indicate potential targets for future combined radiosensitizing strategies.
Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines.
Francesco Marampon,Valentina Di Nisio,Ilaria Pietrantoni,Francesco Petragnano,Irene Fasciani,Bianca Maria Scicchitano,Carmela Ciccarelli,Giovanni Luca Gravina,Claudio Festuccia,Andrea Del Fattore,Mario Tombolini,Francesca De Felice,Daniela Musio,Sandra Cecconi,Paolo Tini,Marta Maddalo,Silvia Codenotti,Alessandro Fanzani,Antonella Polimeni,Roberto Maggio,Vincenzo Tombolini +20 more
TL;DR: In vitro and in vivo data confirm that altered HDACs activity plays a key role in RMS genesis and suggest PXD-101 as a valid therapeutic strategy particularly in combination with RT and cytostatic effects confirmed.
24